688 related articles for article (PubMed ID: 16160477)
21. MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action.
Somaiah N; Tap W
Cancer Treat Rev; 2024 Jan; 122():102668. PubMed ID: 38104352
[TBL] [Abstract][Full Text] [Related]
22. Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas?
Le Guellec S; Chibon F; Ouali M; Perot G; Decouvelaere AV; Robin YM; Larousserie F; Terrier P; Coindre JM; Neuville A
Am J Surg Pathol; 2014 Mar; 38(3):293-304. PubMed ID: 24525499
[TBL] [Abstract][Full Text] [Related]
23. Application of MDM2 Fluorescence In Situ Hybridization and Immunohistochemistry in Distinguishing Dedifferentiated Liposarcoma From Other High-grade Sarcomas.
Song MJ; Cho KJ; Lee JS; Song JS
Appl Immunohistochem Mol Morphol; 2017; 25(10):712-719. PubMed ID: 27028243
[TBL] [Abstract][Full Text] [Related]
24. Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology.
Kim YJ; Kim M; Park HK; Yu DB; Jung K; Song K; Choi YL
Lab Invest; 2019 Sep; 99(9):1309-1320. PubMed ID: 31160689
[TBL] [Abstract][Full Text] [Related]
25. Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma With Features Mimicking Spindle Cell Lipoma.
Jebastin JAS; Perry KD; Chitale DA; Mott MP; Sanchez J; Fritchie KJ; Palanisamy N; Williamson SR
Int J Surg Pathol; 2020 May; 28(3):336-340. PubMed ID: 31672072
[TBL] [Abstract][Full Text] [Related]
26. Well-differentiated and dedifferentiated liposarcomas.
Coindre JM; Pédeutour F; Aurias A
Virchows Arch; 2010 Feb; 456(2):167-79. PubMed ID: 19688222
[TBL] [Abstract][Full Text] [Related]
27. Detection of MDM2 amplification by shallow whole genome sequencing of cell-free DNA of patients with dedifferentiated liposarcoma.
Przybyl J; Spans L; Ganjoo K; Bui N; Mohler D; Norton J; Poultsides G; Debiec-Rychter M; van de Rijn M
PLoS One; 2022; 17(1):e0262272. PubMed ID: 34986184
[TBL] [Abstract][Full Text] [Related]
28. MDM2 and CDK4 Immunohistochemistry: Should It Be Used in Problematic Differentiated Lipomatous Tumors?: A New Perspective.
Clay MR; Martinez AP; Weiss SW; Edgar MA
Am J Surg Pathol; 2016 Dec; 40(12):1647-1652. PubMed ID: 27508976
[TBL] [Abstract][Full Text] [Related]
29. Sensitivity of MDM2 amplification and unexpected multiple faint alphoid 12 (alpha 12 satellite sequences) signals in atypical lipomatous tumor.
Kashima T; Halai D; Ye H; Hing SN; Delaney D; Pollock R; O'Donnell P; Tirabosco R; Flanagan AM
Mod Pathol; 2012 Oct; 25(10):1384-96. PubMed ID: 22699518
[TBL] [Abstract][Full Text] [Related]
30. Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma.
Horvai AE; DeVries S; Roy R; O'Donnell RJ; Waldman F
Mod Pathol; 2009 Nov; 22(11):1477-88. PubMed ID: 19734852
[TBL] [Abstract][Full Text] [Related]
31. GLI1 Coamplification in Well-Differentiated/Dedifferentiated Liposarcomas: Clinicopathologic and Molecular Analysis of 92 Cases.
Sharma AE; Dickson M; Singer S; Hameed MR; Agaram NP
Mod Pathol; 2024 Apr; 37(6):100494. PubMed ID: 38621503
[TBL] [Abstract][Full Text] [Related]
32. Expression of FRS2 in atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: an immunohistochemical analysis of 182 cases with genetic data.
Jing W; Lan T; Qiu Y; Peng R; Lu Y; Chen H; Chen M; He X; Chen C; Zhang H
Diagn Pathol; 2021 Oct; 16(1):96. PubMed ID: 34696768
[TBL] [Abstract][Full Text] [Related]
33. Impact of molecular analysis on the final sarcoma diagnosis: a study on 763 cases collected during a European epidemiological study.
Neuville A; Ranchère-Vince D; Dei Tos AP; Montesco MC; Hostein I; Toffolatti L; Chibon F; Pissaloux D; Alberti L; Decouvelaere AV; Albert S; Rossi CR; Blay JY; Coindre JM
Am J Surg Pathol; 2013 Aug; 37(8):1259-68. PubMed ID: 23774173
[TBL] [Abstract][Full Text] [Related]
34. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors.
Peng T; Zhang P; Liu J; Nguyen T; Bolshakov S; Belousov R; Young ED; Wang X; Brewer K; López-Terrada DH; Oliveira AM; Lazar AJ; Lev D
Lab Invest; 2011 Mar; 91(3):392-403. PubMed ID: 21060307
[TBL] [Abstract][Full Text] [Related]
35. Real-time polymerase chain reaction analysis of MDM2 and CDK4 expression using total RNA from core-needle biopsies is useful for diagnosing adipocytic tumors.
Sasaki T; Ogose A; Kawashima H; Hotta T; Hatano H; Ariizumi T; Umezu H; Ohashi R; Tohyama T; Tanabe N; Endo N
BMC Cancer; 2014 Jun; 14():468. PubMed ID: 24965044
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas.
Saâda-Bouzid E; Burel-Vandenbos F; Ranchère-Vince D; Birtwisle-Peyrottes I; Chetaille B; Bouvier C; Château MC; Peoc'h M; Battistella M; Bazin A; Gal J; Michiels JF; Coindre JM; Pedeutour F; Bianchini L
Mod Pathol; 2015 Nov; 28(11):1404-14. PubMed ID: 26336885
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of MDM2 and CDK4 amplification by real-time PCR on paraffin wax-embedded material: a potential tool for the diagnosis of atypical lipomatous tumours/well-differentiated liposarcomas.
Hostein I; Pelmus M; Aurias A; Pedeutour F; Mathoulin-Pélissier S; Coindre JM
J Pathol; 2004 Jan; 202(1):95-102. PubMed ID: 14694526
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors.
Thway K; Flora R; Shah C; Olmos D; Fisher C
Am J Surg Pathol; 2012 Mar; 36(3):462-9. PubMed ID: 22301498
[TBL] [Abstract][Full Text] [Related]
39. Expression of the preadipocyte marker ZFP423 is dysregulated between well-differentiated and dedifferentiated liposarcoma.
Dang TN; Tiongco RP; Brown LM; Taylor JL; Lyons JM; Lau FH; Floyd ZE
BMC Cancer; 2022 Mar; 22(1):300. PubMed ID: 35313831
[TBL] [Abstract][Full Text] [Related]
40. Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms.
Kyriazoglou A; Pagkali A; Kotsantis I; Economopoulou P; Kyrkasiadou M; Moutafi M; Gavrielatou N; Anastasiou M; Boulouta A; Pantazopoulos A; Giannakakou M; Digklia A; Psyrri A
Cancer Treat Rev; 2024 Apr; 125():102716. PubMed ID: 38492514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
